Rapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in Stock

Key Points

• Insider sold: Krishnaswamy Yeleswaram sold 10,200 shares on April 14 at an average $35.08 for $357,816, trimming his stake by 3.68% to 266,651 shares after several other April sales.
• Stock moved higher: RAPP rose 4.3% to $36.15 on above-average volume (496,199 vs. 328,964) despite a quarterly EPS miss of ($0.72) versus ($0.65) expected and a negative trailing P/E; market cap is about $1.73 billion.
• Analysts and institutions bullish: The consensus rating is "Buy" with an average price target of $53.83, and large institutions (Capital International, Goldman, Vanguard, Baker Bros.) have recently increased their holdings.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 10,200 shares of the stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $35.08, for a total transaction of $357,816.00. Following the completion of the sale, the insider owned 266,651 shares of the company's stock, valued at approximately $9,354,117.08. This represents a 3.68% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.97, for a total transaction of $320,500.05.
• On Friday, April 10th, Krishnaswamy Yeleswaram sold 500 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.98, for a total transaction of $17,490.00.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00.

Rapport Therapeutics Stock Up 4.3%

NASDAQ RAPP traded up $1.50 during trading hours on Tuesday, reaching $36.15. 496,199 shares of the company were exchanged, compared to its average volume of 328,964. Rapport Therapeutics, Inc. has a 1 year low of $7.73 and a 1 year high of $42.27. The business's 50 day simple moving average is $29.41 and its 200-day simple moving average is $28.29. The stock has a market capitalization of $1.73 billion, a P/E ratio of -12.64 and a beta of 1.09.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by ($0.07). As a group, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RAPP shares. Weiss Ratings restated a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Thursday, January 22nd. Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, March 10th. Wells Fargo & Company raised their price objective on shares of Rapport Therapeutics from $43.00 to $46.00 and gave the stock an "overweight" rating in a report on Wednesday, March 11th. BTIG Research raised their price objective on shares of Rapport Therapeutics to $47.00 and gave the stock a "buy" rating in a report on Monday, March 9th. Finally, TD Cowen restated a "buy" rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Rapport Therapeutics has an average rating of "Buy" and a consensus price target of $53.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors boosted its holdings in Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company's stock worth $101,055,000 after buying an additional 800,000 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Rapport Therapeutics by 23.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company's stock worth $91,077,000 after buying an additional 579,903 shares during the period. Vanguard Group Inc. boosted its holdings in Rapport Therapeutics by 11.8% in the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company's stock worth $55,151,000 after buying an additional 191,219 shares during the period. Baker BROS. Advisors LP boosted its holdings in Rapport Therapeutics by 181.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company's stock worth $45,949,000 after buying an additional 997,000 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in Rapport Therapeutics by 4.1% in the 2nd quarter. Alliancebernstein L.P. now owns 1,154,688 shares of the company's stock worth $13,129,000 after buying an additional 45,063 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.